Fellowship Opportunities Available!
LEARN MORE
Improving the Process of Therapeutic Development
Harvard, MIT, and the FDA have partnered to create a center focused on regulatory science, bringing together a range of scientific disciplines that are applied to assess the quality, safety and efficacy of medicinal products and inform regulatory decision-making throughout the lifecycle of a medicine. Working across academia, industry, and government institutions, the Center promotes regulatory science through research and education programs, uniting stakeholders under a common mission: promoting optimal patient health outcomes through biomedical innovation and the availability of safe and effective diagnostics and treatments.
Featured Publications
The Regulatory Science Fellowship Program
Our fellowship program is affiliated with the FDA and focuses on training the next generation of regulatory science researchers. Learn more about the research our fellows are conducting or explore opportunities and how to get involved in our program.
News, Events, & Updates
Innovators in Therapeutics Speaker Series with Ted Love
May 25, 2022, 12:00 – 12:45 pm ET
Twitter @Harvardmit_CRS
This week's CRS newsletter is available to read here ➡️ https://bit.ly/3wpZf8y. Subscribe to have future editions sent directly to your inbox! 🔗https://bit.ly/crsnewsletter
Thank you to the Yale-Mayo Clinic CERSI for giving two CRS fellows the opportunity to present their research at the Virtual Research Seminar today. Excellent work, @ryanpknox and @aoeverhart! #biosimilars #Medicaldevices
Our pleasure! Thank you for such an engaging talk. We hope to see you at future #RegSci Forums.
Big thanks to @HarvardMIT_CRS for opportunity to share my perspective on the digital revolution today at #RegForrum today; esp grateful to all those who took an hour out of their day to attend virtually, including esteemed consultant & author @Frank_S_David (w on-point ? on bmx)
Look forward to discussing these & other topics at tomorrow’s @HarvardMIT_CRS virtual #RegSci forum 🔗https://bit.ly/3vchDmh cc @zakkohane @HarvardDBMI @AEI https://twitter.com/ldtimmerman/status/1521246518937722880
Biopharma: Digitizing, but Not Quite Digital. Perspective from @DShaywitz https://timmermanreport.com/2022/05/biopharmas-digitizing-but-not-quite-digital/
Happening this week! Register soon for AFDO/RAPS Healthcare Products Collaborative's #MedCon 2022, co-sponsored by the @US_FDA. Details here: https://www.healthcareproducts.org/medcon/ #MedicalDeviceRegulation